Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the 'Hottest Trials and Trial Updates 1' session.
Data from the HELIOS-B study supported the recent approvals of AMVUTTRA ® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of vutrisiran for the same indication. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year.
Additional updates to be presented include the design and rationale of the TRITON-CM Phase 3 study of nucresiran (ALN-TTRsc04), an investigational next-generation TTR silencer, in patients with ATTR-CM, as well as an additional analysis from the HELIOS-B study of vutrisiran in patients with ATTR-CM who experienced disease progression while being treated with tafamidis.
Presentation Details
Vutrisiran Reduces All-Cause Mortality, Cardiovascular Mortality, and Cardiovascular Events in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis from the HELIOS-B Trial
Session: Hottest Trials and Trial Updates 1
Saturday, May 17, 11:50 – 11:58 CEST, 5:50 – 5:58 A.M. EST
Presenting Author: Marianna Fontana, United Kingdom
Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan
Session: Novel Insights into Heart Failure Therapeutics
Sunday, May 18, 13:00 – 13:45 CEST, 7:00 – 7:45 A.M. EST
Presenter: Caroline Morbach, Germany
Utility of Genetic Testing For Diagnosing hATTR Patients: Results from a European and Middle East Genetic Testing Program
Session: Novel Insights into Heart Failure Therapeutics
Monday, May 19, 9:00 – 10:00 CEST, 3:00 – 4:00 A.M. EST
Presenter: Antoine Bondue, Belgium
Design and Rationale of a Phase 3 Study to Evaluate Efficacy and Safety of Nucresiran (ALN-TTRsc04) in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Session: Research Methodology
Monday, May 19, 14:00 – 15:00 CEST, 8:00 – 9:00 A.M. EST
Presenter: Marianna Fontana, United Kingdom
Vutrisiran In Patients With Transthyretin Amyloidosis with Cardiomyopathy In HELIOS-B Who Had Progressed On Tafamidis
Session: Evolving Treatment Paradigms in Heart Failure: SGLT2 Inhibition to TTR Stabilisation and Beyond
Tuesday, May 20, 9:21 – 9:30 CEST, 3:21 – 3:30 A.M. EST
Presenter: Jose Gonzalez-Costello, Spain
About AMVUTTRA ® (vutrisiran)
AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild-type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. In Europe, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers. Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease.
About ATTR
Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000 – 300,000 people worldwide. 1-4
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
1 Hawkins PN, Ando Y, Dispenzeri A, et al. Ann Med. 2015;47(8):625-638.
2 Gertz MA. Am J Manag Care. 2017;23(7):S107-S112.
3 Conceicao I, Gonzalez-Duarte A, Obici L, et al. J Peripher Nerv Syst
4 Ando Y, Coelho T, Berk JL, et al. Orphanet J Rare Dis. 2013;8:31.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Clean Jeju Green Tea Cooperative ‘Sumang' to Launch New Hojicha Product This August
JEJU, South Korea, August 18, 2025--(BUSINESS WIRE)--Clean Jeju Green Tea Agricultural Cooperative 'Sumang' has announced that it plans to launch a new product—Hojicha—in August. Hojicha is a roasted green tea made by pan-firing tea leaves at high temperatures, known for its rich, nutty aroma and low caffeine content. Sumang is a vertically integrated producer that grows, processes, and sells organic green tea in Jeju Island. Benefiting from ideal tea-growing conditions—including proximity to the sea, warm temperatures, and frequent mist—the cooperative has been able to cultivate high-quality tea with a consistent moisture supply during the growth period. Recently, global interest in health and wellness has fueled rising demand for matcha, particularly in the United States. Exports have been steadily rising, and inquiries from international buyers are also growing. While many matcha products are flooding the market, consumers often struggle to find high-quality, properly graded matcha. The cooperative's "Sumang Tea Garden" brand offers matcha in three distinct grades: Ceremonial, Premium, and Superior, giving consumers a variety of options tailored to their taste and intended use. CEO Kyungmin Kang said, "While we currently focus on B2B transactions, our ultimate goal is to expand into direct-to-consumer channels with a comprehensive distribution network," adding, "We are committed to offering high-quality products at affordable prices." About Sumang Since 2007, Sumang has produced Jeju green tea of the highest quality, provided by the natural environment of Jeju Island, South Korea. Abiding by the strict rules of the Clean Jeju Green Tea Agricultural Cooperative, Sumang offers products that promote both health and environmental sustainability. View source version on Contacts SumangKyungmin Kang+82-64-739-8033tolkm@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21 minutes ago
- Business Wire
Clean Jeju Green Tea Cooperative ‘Sumang' to Launch New Hojicha Product This August
BUSINESS WIRE)-- Clean Jeju Green Tea Agricultural Cooperative 'Sumang' has announced that it plans to launch a new product—Hojicha—in August. Hojicha is a roasted green tea made by pan-firing tea leaves at high temperatures, known for its rich, nutty aroma and low caffeine content. 'While we currently focus on B2B transactions, our ultimate goal is to expand into direct-to-consumer channels with a comprehensive distribution network.' Sumang is a vertically integrated producer that grows, processes, and sells organic green tea in Jeju Island. Benefiting from ideal tea-growing conditions—including proximity to the sea, warm temperatures, and frequent mist—the cooperative has been able to cultivate high-quality tea with a consistent moisture supply during the growth period. Recently, global interest in health and wellness has fueled rising demand for matcha, particularly in the United States. Exports have been steadily rising, and inquiries from international buyers are also growing. While many matcha products are flooding the market, consumers often struggle to find high-quality, properly graded matcha. The cooperative's 'Sumang Tea Garden' brand offers matcha in three distinct grades: Ceremonial, Premium, and Superior, giving consumers a variety of options tailored to their taste and intended use. CEO Kyungmin Kang said, 'While we currently focus on B2B transactions, our ultimate goal is to expand into direct-to-consumer channels with a comprehensive distribution network,' adding, 'We are committed to offering high-quality products at affordable prices.' About Sumang Since 2007, Sumang has produced Jeju green tea of the highest quality, provided by the natural environment of Jeju Island, South Korea. Abiding by the strict rules of the Clean Jeju Green Tea Agricultural Cooperative, Sumang offers products that promote both health and environmental sustainability.
Business Wire
21 minutes ago
- Business Wire
Bragg Gaming Group Announces Cyber Security Incident
TORONTO--(BUSINESS WIRE)--Bragg Gaming Group (BRAG:CA) ('Bragg' or the 'Company'), a leading content and technology provider to the online gaming industry, today announced the Company learned of a cybersecurity incident early Saturday morning, August 16, 2025, CEST time. Bragg has taken immediate steps to mitigate any potential impact. Additional independent cybersecurity experts have been retained to assist the Company in dealing with the matter in accordance with industry best practices. Based on preliminary investigations, the Company believes that the data breach was limited to Bragg's internal computer environment. At the present time, there is no indication that any personal information was affected. Additionally, the breach has had no impact on the ability of the Company to continue its operations, nor has it been restricted from accessing any data that has been subject to the breach. Bragg is committed to data safety, is taking the matter very seriously and asks its customers and partners for their patience as it seeks to remediate the situation. The latest information regarding the incident will be made available on and updated as further developments occur. Cautionary Statement Regarding Forward-Looking Information This news release contains forward-looking statements or 'forward-looking information' within the meaning of applicable Canadian securities laws ('forward-looking statements'), including, without limitation, statements with respect to the following: the Company's plans to address the cyber security incident and its expected impact on Bragg's operations and the safety and security of its customers and partners data. Forward-looking statements are provided for the purpose of presenting information about management's current expectations and plans relating to the future and allowing readers to get a better understanding of the Company's anticipated financial position, results of operations, and operating environment. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or describes a 'goal', or variation of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. All forward-looking statements contained in this news release reflect the Company's beliefs and assumptions based on information available at the time the statements were made. Actual results or events may differ from those predicted in these forward-looking statements. All of the Company's forward-looking statements are qualified by the assumptions that are stated or inherent in such forward-looking statements, including the assumptions listed below. Although the Company believes that these assumptions are reasonable, this list is not exhaustive of factors that may affect any of the forward-looking statements. Specifically, the forward-looking statements herein are subject to the risk that the investigation of the cyber security breach is in its initial stages so the assessment of the potential impact could change over time as more information gathered. Forward-looking information, by its very nature, is subject to numerous risks and uncertainties and is based on several assumptions which give rise to the possibility that actual results could differ materially from the Company's expectations expressed in or implied by such forward-looking information and no assurance can be given that any events anticipated by the forward-looking information will transpire or occur, including but not limited to the timing for the investigation and recovery process, the impact on Bragg's business operations, future plans, activities, objectives, operations, strategy, business outlook and financial performance and condition of the Company. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except in accordance with applicable securities laws. About Bragg Gaming Group Bragg Gaming Group (NASDAQ: BRAG, TSX: BRAG) is an iGaming content and turnkey technology solutions provider serving online and land-based gaming operators with its proprietary and exclusive content, and cutting-edge technology. Bragg Studios offer high-performing and passionately crafted casino game titles using the latest in data-driven insights from in-house brands including Wild Streak Gaming, Atomic Slot Lab and Indigo Magic. Its proprietary content portfolio is complemented by a cross section of exclusive titles from carefully selected studio partners under the Powered By Bragg program. Games built on Bragg's remote games server (Bragg RGS) technology are distributed via the Bragg Hub content delivery platform and are available exclusively to Bragg customers. Bragg's flexible, modern, omnichannel Player Account Management (PAM) platform powers multiple leading iCasino and sportsbook brands and at all points is supported by expert in-house managed, operational, and marketing services. Content delivered via the Bragg Hub either exclusively or from the Bragg aggregated games portfolio is managed from a single back-office which is supported by powerful data analytics tools, and Bragg's award-winning FuzeTM player engagement toolset. Bragg is licensed, certified, approved and operational in many regulated iCasino markets globally, including the U.S., Canada, Brazil, United Kingdom, Italy, the Netherlands, Germany, Sweden, Spain, Malta and Colombia. Twitter LinkedIn Facebook Instagram
